Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH). The company reiterated its plans to submit regulatory applications

Read the full 424 word article

User Sign In